Oryzon Genomics S.A. (BME:ORY)

Market Cap	263.76M
Revenue (ttm)	7.47M
Net Income (ttm)	-4.22M
Shares Out	78.85M
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,552,508
Average Volume	1,396,882
Open	3.340
Previous Close	3.345
Day's Range	3.315 - 3.535
52-Week Range	1.400 - 3.690
Beta	0.45
RSI	67.79
Earnings Date	Oct 27, 2025

About Oryzon Genomics

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical developme...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 47
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ORY

Financial Performance

In 2024, Oryzon Genomics's revenue was 7.36 million, a decrease of -48.15% compared to the previous year's 14.19 million. Losses were -3.67 million, 9.32% more than in 2023.